Uncategorized
ThromboGenics reports €12.2 million loss between second, third quarters
ThromboGenics reported cash and investments totaling €136.6 million at the end of the third quarter, down from €148.8 million at the end of the second quarter.However, according to a press release, the company is optimistic that cash flow and revenues will reach targets in the near term.